Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

Tue, 26th Oct 2021 19:06

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Yellow Cake PLC - Jersey-based investor in uranium - Plans to raise USD150 million through placing. Will fund purchase of three millions pounds of physical uranium. "The long term outlook for the uranium price remains strong, driven by the more positive demand outlook and on-going supply constraints, causing the supply deficit to grow every year. We continue to seek further opportunities for value accretive opportunistic uranium purchases at an attractive price," Chief Executive Officer Andre Liebenberg says.

----------

Mercia Asset Management PLC - West Midlands-based asset manager - Completes GBP1.8 million investment into new portfolio company Forensic Analytics Ltd, alongside GBP2.7 million backing by Mercia managed Northern VCTs. "Following this investment, Mercia holds an 8.9% fully diluted direct equity stake in Forensic Analytics, with the Northern VCTs holding a further 13.9% fully diluted equity stake," Mercia says.

----------

Tern PLC - investor focused on the internet of things - Says "significant business momentum" continues across principal portfolio firms. Device Authority Ltd investee launches KeyScaler Edge offering to address IoT security challenges. "In addition to new customer wins and repeat orders, Device Authority have recently entered into further distribution partnerships, including with Trusted Objects, a leading independent player in cybersecurity technologies for embedded systems and cloud device management platforms, and with Titan Automotive Solutions, a leading provider of car connectivity solutions with a global presence," Tern says. Tern owns 57% of Device Authority. Virtual reality focused investee FVRVS Ltd, meanwhile, wins deal with company previously using a competitor's product. InVMA Ltd sees "strong sales growth", while Wyld Networks AB "continued to make further significant progress following its IPO on the NASDAQ First North Growth Market in Stockholm".

----------

Path Investments PLC - Bingley, England-based natural resources investment company - Says longstop date for DG Innovate Ltd buy extended to December 31. "Path and its advisers continue to progress the proposed transaction," company says.

----------

Caerus Mineral Resources PLC - London-based exploration & resource development company - Says trenching of stockpiles at Troulli project finds "very high-grade visible copper mineralisation". Copper grades are "highly significant", based on semi-quantitative XRF analysis. "Samples have been collected and are ready for dispatch to the assay laboratory," Caerus says. Duplicate samples also sent to partner Jubilee Metals Group PLC for testwork.

----------

Petra Diamonds Ltd - London-based diamond miner - Says revenue in first quarter ended September 30 improves year-on-year to USD114.9 million from USD77.7 million a year earlier. Says output falls annually to 861,991 carats from 974,346 carats.

----------

IMC Exploration Group PLC - Dublin-based exploration company focused on Ireland - Says drillhole 21-3850-01 at West Avoca encounters "four zones of massive and semi massive sulphide mineralisation". Says 18.7 metre interval or zinc, lead and silver mineralisation found. "IMC plans that the drill programme will allow an independent resource calculation to be undertaken in addition to that already in place for the spoils' and tailings' project," IMC adds.

----------

Angus Energy PLC - oil & gas development company - Shares revised competent persons report at Saltfleetby gas field. Says conservative estimate, or P90, of future cashflows to Angus stands at GBP31.7 million. Mid-case, or P50, has it at GBP55.9 million. Angus adds: "In summary the report estimates production giving rise to gross field revenues, before costs on a mid-case basis of GBP230 million (previously GBP141 million) of which Angus's share is 51%."

----------

Oxford Metrics PLC - software company servicing infrastructure, life sciences, entertainment and engineering markets - Says motion measurement unit Vicon wins deal with volumetric content and virtual production firm Dimension Studios. "Vicon's tracking, of both rigid and full body subjects, will be used alongside Dimension Studio's volumetric and real-time development capabilities by leading visual effects company DNEG for several high-profile virtual production projects - including a major motion picture and a 10-hour TV series," Oxford Metrics says.

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says third quarter sales "strong" at USD964,000. "Importantly, both the September and June 2021 quarters combined have delivered a record USD2.24 million in cash receipts from customers over the 6-month period, with increasing month on month sales generated from new key markets, such as the UK and Ireland," MGC adds.

----------

ReNeuron Group PLC - Bridgend, Wales-based exosome therapeutics company - Teams with University College London to research generation of immune cells from induced pluripotent stem cells as a potential cancer therapy. ReNeuron will provide UCL with the stem cells. Company adds: "Induced pluripotent stem cells can differentiate into any cell type found in the body, but unlike most iPSCs, ReNeuron's proprietary CTX-iPSCs carry the conditional immortalisation system incorporated into CTX. ReNeuron's CTX derived iPSC's are available as clinical grade material potentially allowing faster development of arising therapeutics and the company believes that its conditional immortalisation technology could allow the company to manufacture cost efficiently at scale to treat large numbers of patients providing 'off the shelf' cell therapies."

----------

Omni Egis PLC - debt financing solutions provider for small to medium-sized businesses - Says AQSE listing "not commercial for the company to raise funds at the current share price". Notes market capitalisation currently below liquid resources. Convenes general meeting on November 18 to vote on AQSE withdrawal.

----------

CATCo Reinsurance Opportunities Fund Ltd - invests in catastrophe reinsurance risks - Receives "substantial level of investor support" for Markel CATCo Investment Management Ltd-funded buyout. Markel is CATCo's manager.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
15 Apr 2014 12:23

ReNeuron leases building for relocation of business

AIM-listed ReNeuron has signed a deal with the Welsh government to lease a landmark building at Pencoed Technology Park, near Cardiff in South Wales. The stem cell therapy company explained that it will build a new state-of-the-art facility at Pencoed, to which it will relocate the business next ye

Read more
15 Apr 2014 10:01

ReNeuron Leases New Research & Development Facility With Welsh Government

LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC said Tuesday that it had signed an agreement with the Welsh Government to lease a new research and development facility at the Pencoed Technology Park near Cardiff, South Wales. ReNeuron expects to begin to relocate its o

Read more
15 Apr 2014 07:50

UK MORNING BRIEFING: Aggreko Leads After Mixed Results

LONDON (Alliance News) - Aggreko is leading the FTSE 100 in early trading Tuesday after the temporary power company said it has seen mixed results in its first quarter, with strong underlying revenue growth in two of its three regions being impacted by adverse currency movements as previously exp

Read more
27 Mar 2014 13:48

UK MIDDAY BRIEFING: Regulators Confirm UK Energy Market Review

LONDON (Alliance News) - UK regulators have now confirmed they will investigate whether the country's major energy companies are preventing effective competition in the market, a decision that prompted British Gas parent Centrica to warn that the review could delay crucial investments in new i

Read more
27 Mar 2014 13:01

UK WINNERS & LOSERS: Babcock, Tullow Oil Lead Blue-Chip Fallers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.

-------

FTSE 100 - WINNERS

Old Mutual, up 0.5%. The group has agreed to sell Skandia Germany and S

Read more
27 Mar 2014 11:13

ReNeuron Gets Approvals To Begin Two New Trials Using Stem Cell Product

LONDON (Alliance News) - ReNeuron Group PLC said Thursday that it has received final regulatory and ethical approvals to begin two new clinical trials using its CTXcyro stem cell product. The company will begin a Phase II clinical trial of its ReN001 investigational therapy in stroke disabi

Read more
14 Mar 2014 13:04

ReNeuron Eyes New UK Government Scheme Encouraging Novel Therapies

LONDON (Alliance News) - ReNeuron Group PLC Friday said it will look at whether the UK government's plan to launch a scheme to encourage the take up of novel therapies could be applied to its own therapeutic candidates. The scheme, called the Early Access to Medicines Scheme, is looking to

Read more
11 Mar 2014 12:48

US foundation funds ReNeuron stem cell therapy

A US-based charity has agreed to provide funding and access to clinical expertise for ReNeuron's retinal stem cell therapy candidate for a degenerative eye disease. Shares in ReNeuron rose 8.8% to 3.54p on the news. The Foundation for Fighting Blindess has agreed to provide further funding toward

Read more
11 Mar 2014 11:27

ReNeuron Retinal Stem Cell System Wins FFB Support

LONDON (Alliance News) - ReNeuron Group PLC said Tuesday its retinal stem cell therapy candidate is to receive support from a retinal research funding foundation. ReNeuron said its ReN003 retinal stem cell therapy candidate for the treatment of retinis pigmentosa is set to receive support

Read more
21 Jan 2014 10:04

ReNeuron Sees Positive Data For Stem Cells In Retinal Degeneration Test

LONDON (Alliance News) - ReNeuron Group PLC said Tuesday that a paper detailing the efficiency of its human retinal stem cells in a test model of retinal degeneration had been published in the Journal of Biological Chemistry. The test showed that ReNeuron's cells protected visual function w

Read more
21 Jan 2014 08:19

UK MORNING BRIEFING: Shares Higher; Unilever, SABMiller As Expected

LONDON (Alliance News) - UK shares have opened higher Tuesday, as Unilever and SABMiller have released results and trading statements in line with expectations.

Peel Hunt has issued ratings on the property sector, cutting Great Portland Est

Read more
13 Sep 2013 09:02

ReNeuron Moving All Therapeutic Programmes To Phase II Trials In Next 3 Years

Read more
22 Jul 2013 10:50

ReNeuron announces capital increase, funds to enter capital structure

Lifesciences group ReNeuron has announced that it has successfully raised 33m pounds in fresh funding to finance its research into stem-cell development, although it had to offer a small discount for the new equity. Significantly, three new investment funds are to enter its shareholder register with

Read more
28 May 2013 10:39

ReNeuron jumps on stem cell study results

Shares in AIM-listed stem cell business ReNeuron Group rose on Tuesday morning after the group unveiled details of progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. The group said that the primary aim of the study was to test the safety and toler

Read more
26 Mar 2013 09:45

ReNeuron Group to begin stem cell treatment of critical limb ischaemia

ReNeuron Group has received regulatory approval to begin the first phase of a clinical trial in the UK for the company's ReN009 stem cell therapy treatment for critical limb ischaemia. Critical limb ischaemia, a condition which leads to blood vessel blockage in limbs such as toes and can lead to am

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account